Exelixis Inc Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
Exelixis Inc (EXEL) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $20.05 per share for the 12-month period ending 2026-01-02, per its 10-K filed 2026-02-10.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2026-02-10
- Exelixis Inc share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2019-03-29 was $4.91, a 26.61% decline year-over-year.
- Exelixis Inc share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2018-03-30 was $6.69, a 55.94% increase year-over-year.
- Exelixis Inc share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2017-03-31 was $4.29, a 152.35% increase year-over-year.
- Exelixis Inc share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2016-03-31 was $1.70.
- Exelixis Inc share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2026 was $20.05, a 7.94% decline from fiscal 2025.
- Exelixis Inc share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2025 was $21.78, a 69.63% increase from fiscal 2023.
- Exelixis Inc share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2023 was $12.84, a 123.69% increase from fiscal 2022.
- Exelixis Inc share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2022 was $5.74, a 35.70% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-01-02 | $20.05 10-K · filed 2026-02-10 | |||
| 2025-01-03 | $21.78 10-K · filed 2025-02-11 | |||
| 2023-12-29 | $12.84 10-K · filed 2024-02-06 | |||
| 2022-12-30 | $5.74 10-K · filed 2023-02-07 | |||
| 2021-12-31 | $4.23 10-K · filed 2022-02-18 | |||
| 2021-01-01 | $4.77 10-K · filed 2021-02-11 | |||
| 2020-01-03 | $5.01 10-K · filed 2020-02-25 | |||
| 2019-09-27 | $4.94 10-Q · filed 2019-10-30 | |||
| 2019-06-28 | $4.93 10-Q · filed 2019-07-31 | |||
| 2019-03-29 | $4.91 10-Q · filed 2019-05-01 | |||
| 2018-12-28 | $4.90 10-K · filed 2019-02-22 | |||
| 2018-09-28 | $5.01 10-Q · filed 2018-11-01 | |||
| 2018-06-29 | $5.74 10-Q · filed 2018-08-01 | |||
| 2018-03-30 | $6.69 10-Q · filed 2018-05-02 | |||
| 2017-12-29 | $3.91 10-K · filed 2018-02-26 | |||
| 2017-09-30 | $3.94 10-Q · filed 2017-11-01 | |||
| 2017-06-30 | $4.04 10-Q · filed 2017-08-02 | |||
| 2017-03-31 | $4.29 10-Q · filed 2017-05-01 | |||
| 2016-12-31 | $4.07 10-K · filed 2017-02-27 | |||
| 2016-09-30 | $2.81 10-Q · filed 2016-11-03 | |||
| 2016-06-30 | $1.89 10-Q · filed 2016-08-03 | |||
| 2016-03-31 | $1.70 10-Q · filed 2016-05-04 | |||
| 2015-12-31 | $4.66 10-K · filed 2016-02-29 | |||
| 2015-09-30 | $4.33 10-Q · filed 2015-11-10 | |||
| 2014-12-31 | $6.28 10-K · filed 2015-03-02 | |||
| 2014-09-30 | $6.28 10-Q · filed 2014-11-04 | |||
| 2014-06-30 | $6.28 10-Q · filed 2014-07-31 | |||
| 2014-03-31 | $6.28 10-Q · filed 2014-05-01 | |||
| 2013-12-31 | $5.06 10-K · filed 2015-03-02 | |||
| 2013-09-30 | $4.42 10-Q · filed 2013-10-30 | |||
| 2013-06-30 | $4.42 10-Q · filed 2013-08-06 | |||
| 2013-03-31 | $4.42 10-Q · filed 2013-05-07 | |||
| 2012-12-31 | $5.09 10-K · filed 2015-03-02 | |||
| 2012-09-30 | $5.12 10-Q · filed 2012-11-07 | |||
| 2011-12-31 | $5.75 10-K · filed 2014-02-20 | |||
| 2010-12-31 | $5.42 10-K · filed 2013-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |